167 Detection of non-metastatic non-small cell lung cancer in urine 29. Lababede O, Meziane MA. The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams. Oncologist. 2018;23(7):844-8. 30. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-5. 31. Marshall R. The Predictive Value of Simple Rules for Combining Two Diagnostic Tests. Biometrics. 1989;45:1213-22. 32. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. 33. Bach S, Paulis I, Sluiter NR, Tibbesma M, Martin I, van de Wiel MA, et al. Detection of colorectal cancer in urine using DNA methylation analysis. Scientific Reports. 2021;11(1):2363. 34. Goldman JW, Karlovich C, Sequist LV, Melnikova V, Franovic A, Gadgeel SM, et al. EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non–Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO Precision Oncology. 2018(2):1-13. 35. Hu T, Shen H, Huang H, Song M, Yang Z, Zhou Y, et al. Urinary circulating DNA profiling in non-small cell lung cancer patients following treatment shows prognostic potential. Journal of Thoracic Disease. 2018;10(7):4137-46. 36. Yu H, Liu M, Qiu H, Yang K. Urinary and Plasma Cell-Free DNA Comparison for Lung Cancer Patients Treated With Epidermal Growth Factor Receptor—Thyroxine Kinase Inhibitors. The American Journal of the Medical Sciences. 2019;357(1):29-36. 37. Franovic A, Raymond VM, Erlander MG, Reckamp KL. Urine test for EGFR analysis in patients with non-small cell lung cancer. Journal of thoracic disease. 2017;9(Suppl 13):S1323-S31. 38. Wu Z, Yang Z, Li CS, Zhao W, Liang ZX, Dai Y, et al. Non‑invasive detection of EGFR and TP53 mutations through the combination of plasma, urine and sputum in advanced non‑small cell lung cancer. Oncol Lett. 2019;18(4):3581-90. 39. Wu Z, Yang Z, Li CS, Zhao W, Liang ZX, Dai Y, et al. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC. Cancer Medicine. 2019;8(3):910-9. 40. Tchekmedyian N, Mudad R, Blanco FF, Raymond VM, Garst J, Erlander MG, et al. Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series. Lung Cancer. 2017;108:22-8. 41. Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, et al. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clin Cancer Res. 2017;23(16):4716-23. 42. Kang G, Chen K, Yang F, Chuai S, Zhao H, Zhang K, et al. Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: protocol for a prospective observational study. BMC Cancer. 2019;19(1):579. 43. Horvath S, Zhang Y, Langfelder P, Kahn RS, Boks MP, van Eijk K, et al. Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol. 2012;13(10):R97. 44. Zeilinger S, Kuhnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C, et al. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS One. 2013;8(5):e63812. 6
RkJQdWJsaXNoZXIy MjY0ODMw